Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (Weill Cornell Medicine)
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is a live biotherapeutic intervention being investigated by Weill Medical College of Cornell University (Weill Cornell Medicine) for the treatment of ulcerative colitis. The procedure involves the administration of a purified fecal microbiota preparation (FMP), typically sourced from healthy donors (such as through OpenBiome), into the colon of patients via colonoscopy. The therapeutic goal is to restore microbial diversity and correct the dysbiosis associated with ulcerative colitis. Research led by Dr. Randy Longman at Weill Cornell has identified that specific bacterial strains within the transplant, notably *Odoribacter splanchnicus*, contribute to efficacy by inducing anti-inflammatory regulatory T cells, stimulating the production of interleukin-10 (IL-10), and generating short-chain fatty acids like butyrate, which help resolve intestinal inflammation.
- Other names
- FMTFecal Microbiota TransplantationFecal Microbiota PreparationFMP
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on fecal microbiota transplantation (Weill Cornell Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (Weill Cornell Medicine).